Market Currents
The FDA's approval of Actavis' generic Adderall XR will be a positive for Watson Pharmaceuticals...
-
Monday, June 25, 2012, 2:04 PM ETThe FDA's approval of Actavis' generic Adderall XR will be a positive for Watson Pharmaceuticals (WPI +1%), which is acquiring the company, says Goldman. The firm says the news supports its above consensus earnings estimates, adding that it sees only modest impact to TEVA and IPXL.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
